Realm Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

Wednesday, August 8, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

MALVERN, Pa., Aug. 8, 2018 /PRNewswire/ -- Realm Therapeutics plc (NASDAQ: RLM / AIM: RLM), a clinical stage biopharmaceutical

company focused on developing novel therapeutics in immune-mediated diseases, announces today that Alex Martin, CEO, will be presenting at the 2018 Wedbush PacGrow Healthcare Conference, on Tuesday, August 14, 2018 at 4:15 p.m. ET at the Parker New York.

A

live and archived webcast of the Wedbush presentation will be available on the Events and Presentations page of the Company's website at www.realmtx.com.

About Realm Therapeutics

Realm Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics that target the interplay between innate and adaptive immunity. The Company's programs seek to influence immune signalling and change the course of immune-mediated diseases in adults and children. Realm's lead drug development program utilizes the Company's proprietary immunomodulatory technology for the treatment of Atopic Dermatitis, and the Company is exploring its efficacy in other dermatology indications which include Acne Vulgaris, and Psoriasis, as well as other therapeutic areas. For more information on Realm Therapeutics please visit www.realmtx.com.

G-RLM

Contacts:

Realm Therapeutics plcAlex Martin, Chief Executive OfficerMarella Thorell, Chief Financial Officer and Chief Operating Officer Outside US:  +44 (0) 20 3727 1000 US:  +1 212 600 1902

Argot PartnersStephanie Marks / Claudia Styslinger+1 212 600 1902

FTI ConsultingSimon Conway / Mo Noonan+44 (0) 20 3727 1000

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer+44 (0) 20 7496 3000

Cision View original content:http://www.prnewswire.com/news-releases/realm-therapeutics-to-present-at-the-2018-wedbush-pacgrow-healthcare-conference-300693471.html

SOURCE Realm Therapeutics



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store